全球结核病存活者数量建模研究
BACKGROUND: People who survive tuberculosis face clinical and societal consequences after recovery, including increased risks of recurrent tuberculosis, premature death, reduced lung function, and ongoing stigma.…
要点
- 1980-2019年结核病发生者至2020年共存活3480万生命年。
- 近期治疗过的存活者应优先干预呼吸疾病、复发筛查和污名。
研究设计与样本
- 建模研究,使用WHO国家结核病通报和发病数据,结合年龄和HIV分层病死率及UN人口死亡率构建病后生命表。
主要发现
- 至2020年,结核病发生者共存活3480万生命年(95%UI 3040万-3920万),结核病发生时小于15岁者贡献12%(95%UI 7-17)。
- 2020年存活者中18%(95%UI 16-20)在过去5年内治疗,8%(95%UI 7-9)在过去2年内治疗。
临床怎么用
- 对近期治疗过的结核病存活者,应优先开展呼吸疾病缓解、复发筛查和预防及减少污名的干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People who survive tuberculosis face clinical and societal consequences after recovery, including increased risks of recurrent tuberculosis, premature death, reduced lung function, and ongoing stigma. To describe the size of this issue, we aimed to estimate the number of individuals who developed first-episode tuberculosis between 1980 and 2019, the number who survived to 2020, and the number who have been treated within the past 5 years or 2 years. METHODS: In this modelling study, we estimated the number of people who survived treated tuberculosis using country-level WHO data on tuberculosis case notifications, excluding those who died during treatment. We estimated the number of individuals surviving untreated tuberculosis using the difference between WHO country-level incidence estimates and notifications, applying published age-stratified and HIV-stratified case fatality ratios. To estimate survival with time, post-tuberculosis life tables were developed for each country-year by use of UN World Population Prospects 2019 mortality rates and published post-tuberculosis mortality hazard ratios. FINDINGS: Between 1980 and 2019, we estimate that 363 million people (95% uncertainty interval [UI] 287 million-438 million) developed tuberculosis, of whom 172 million (169 million-174 million) were treated. Individuals who developed tuberculosis between 1980 and 2019 had lived 3480 million life-years (95% UI 3040 million-3920 million) after tuberculosis by 2020, with survivors younger than 15 years at the time of tuberculosis development contributing 12% (95% UI 7-17) of these life-years. We estimate that 155 million tuberculosis survivors (95% UI 138 million-171 million) were alive in 2020, the largest proportion (47% [37-57]) of whom were in the WHO South-East Asia region. Of the tuberculosis survivors who were alive in 2020, we estimate that 18% (95% UI 16-20) were treated in the past 5 years and 8% (7-9) were treated in the past 2 years. INTERPRETATION: The number of tuberculosis survivors alive in 2020 is more than ten times the estimated annual tuberculosis incidence. Interventions to alleviate respiratory morbidity, screen for and prevent recurrent tuberculosis, and reduce stigma should be immediately prioritised for recently treated tuberculosis survivors. FUNDING: UK Medical Research Council, the UK Department for International Development, the National Institute for Health Research, and the European and Developing Countries Clinical Trials Partnership.
引用
- Dodd PJ, Yuen CM, Jayasooriya SM, et al. Quantifying the global number of tuberculosis survivors: a modelling study. Lancet Infect Dis. 2021. PMID: 33640076. doi:10.1016/S1473-3099(20)30919-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。